Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FULCRUM THERAPEUTICS, INC.

(FULC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/20/2021 07/21/2021 07/22/2021 07/23/2021 07/26/2021 Date
10.03(c) 9.08(c) 8.44(c) 8(c) 7.56(c) Last
384 481 360 504 160 282 148 762 74 446 Volume
+1.93% -9.47% -7.05% -5.21% -5.50% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 9,70 M - -
Net income 2021 -88,6 M - -
Net cash position 2021 78,2 M - -
P/E ratio 2021 -2,88x
Yield 2021 -
Sales 2022 11,2 M - -
Net income 2022 -113 M - -
Net cash position 2022 161 M - -
P/E ratio 2022 -2,71x
Yield 2022 -
Capitalization 246 M 246 M -
EV / Sales 2021 17,3x
EV / Sales 2022 7,59x
Nbr of Employees 73
Free-Float 91,7%
More Financials
Company
Fulcrum Therapeutics, Inc. clinical-stage biopharmaceutical company. The Company focuses on improving the lives of patients with genetically defined rare diseases. The Company have developed a product engine which identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The Company is also engaged in developing drugs for the treatment for the root cause of... 
More about the company
Ratings of Fulcrum Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about FULCRUM THERAPEUTICS, INC.
07/14FULCRUM THERAPEUTICS : IRC 2021 RNAseq Presentation
PU
06/25FULCRUM THERAPEUTICS : Announces Results from ReDUX4 Trial with Losmapimod in Fa..
AQ
06/25FULCRUM THERAPEUTICS : ReDUX4 Data
PU
06/25FULCRUM THERAPEUTICS, INC.(NASDAQGM : FULC) added to Russell Microcap Value Inde..
CI
06/25FULCRUM THERAPEUTICS, INC.(NASDAQGM : FULC) dropped from Russell Small Cap Comp ..
CI
06/25FULCRUM THERAPEUTICS, INC.(NASDAQGM : FULC) added to Russell Small Cap Comp Valu..
CI
06/25FULCRUM THERAPEUTICS, INC.(NASDAQGM : FULC) dropped from Russell Microcap Growth..
CI
06/25FULCRUM THERAPEUTICS, INC.(NASDAQGM : FULC) dropped from Russell 3000E Growth In..
CI
06/25FULCRUM THERAPEUTICS, INC.(NASDAQGM : FULC) added to Russell 3000E Value Index
CI
06/25FULCRUM THERAPEUTICS, INC.(NASDAQGM : FULC) added to Russell 2000 Value Index
CI
06/25FULCRUM THERAPEUTICS, INC.(NASDAQGM : FULC) dropped from Russell 2500 Growth Ind..
CI
06/25FULCRUM THERAPEUTICS, INC.(NASDAQGM : FULC) added to Russell 2500 Value Index
CI
06/25FULCRUM THERAPEUTICS, INC.(NASDAQGM : FULC) dropped from Russell 2000 Growth Ind..
CI
06/25FULCRUM THERAPEUTICS, INC.(NASDAQGM : FULC) dropped from Russell 3000 Growth Ind..
CI
06/25FULCRUM THERAPEUTICS, INC.(NASDAQGM : FULC) added to Russell 3000 Value Index
CI
More news
News in other languages on FULCRUM THERAPEUTICS, INC.

- No features available -

More news
Analyst Recommendations on FULCRUM THERAPEUTICS, INC.
More recommendations
Chart FULCRUM THERAPEUTICS, INC.
Duration : Period :
Fulcrum Therapeutics, Inc. Technical Analysis Chart | FULC | US3596161097 | MarketScreener
Technical analysis trends FULCRUM THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 7,56 $
Average target price 20,71 $
Spread / Average Target 174%
EPS Revisions
Managers and Directors
Bryan E Stuart President, Chief Executive Officer, COO & Director
Peter Thomson Chief Financial Officer & VP-Finance & Accounting
Mark Jay Levin Executive Chairman
Christopher Moxham Chief Scientific Officer
Christopher J Morabito Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
FULCRUM THERAPEUTICS, INC.-35.44%246
MODERNA, INC.221.50%140 065
LONZA GROUP AG20.60%55 634
IQVIA HOLDINGS INC.38.02%47 396
CELLTRION, INC.-26.46%31 265
SEAGEN INC.-18.34%25 955